Human Papillomavirus (HPV) Vaccines

//Human Papillomavirus (HPV) Vaccines

Adverse Effects

“Autoimmune disorders, including juvenile, rheumatoid, reactive and nonspecified arthritis have occurred at a higher rate among vaccine recipients than among placebo recipients, but the clinical significance of this finding is unknown.”

Injection site pain, swelling, death, erythema, pruritus, fever, nausea, nasopharyngitis, dizziness, diarrhea, vomiting, myalgia, cough, toothache, upper respiratory infection, malaise, arthralgia, insomnia, nasal congestion were also commonly oberved.


“Safety and efficacy not established in patients younger than 9 years or older than 26 years. Not recommended during pregnancy; caution recommended during lactation.”

Unwise Investment

The vaccine is being promoted as costing $360 dollars per person (3 injections) but many pay $400 to $450 or the shots. This is prohibitively expensive compared to proven, accessible, affordable prevention screening tests. To invest that amount of healthcare dollars in a vaccination with no long term efficacy or safety data is unwise.

No Studies Performed

Gardasil has not been examined for possible carcinogenic, mutagenic, or teratogenic effects

Postponing Disease to Higher Risk Group

Seventy percent of women clear the virus spontaneously after 18 months and 90 % clear the virus after 2 years. Vaccinating children with an HPV of unknown efficacy duration may only postpone their exposure to an age which they are less likely clear the infection on their own and be subject to more severe disease, including the cervical cancer — which the vaccine is supposedly preventing. This could be recipe for disaster. It is WAVE’s prediction, observing the path of other vaccines, that boosters will then be recommended and added to the growing list of mandatory shots.


Centers for Disease Control and Prevention. Genital HPV Infection Facts Sheet.

There has been much hooraying over the first “cancer vaccine.” The drug companies and medical establishments are oddly united in celebration over the idea alone, as if the vaccine’s it’s mere creation was a triumph. But there are significant problems that indicate that this may be premature, at best.

Inappropriate Claims — NOT a Cancer Vaccine

Follow-up period in studies lasted only four years. But the time course from acquiring the virus to invasive cancer averages between 8.1 to 12.6 years (1). The HPV vaccine does not fight, attack or otherwise “cure” cancer. It is a vaccine against the human papillomavirus (HPV). Claiming this vaccine prevents cervical cancer (with the longest median study subject being 4 years) is inappropriate and is more a promotional tool than an accurate descriptor.

Many Strains, Many Mutations, May Possibilities

HPV is not a single virus entity – over 200 sub-types have been identified, 30 of which are known to infect the genital tract. HPV 6, 11, 42, 43 and 44 are classified as low-risk (for cancer), while 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70 are considered to be the “high-risk” subtypes depending on the population studied.

Viral particles of subtypes 6, 11, 16 and 18 are used in the Gardasil (HPV) vaccine. This may lead to an increase in infection with other and possibly more aggressive subtypes. Claiming any victory over cervical cancer is mere guesswork.

Two new studies from Alaska and from Spain suggest that serotypes or strains of pneumococcal bacteria not covered in the vaccine — sold as Prevnar — are stepping into the void left by those the vaccine protects against. “I think we knew there was that potential for that to occur, but there was no way to predict if it would occur or to what extent,” Dr. Rosalyn Singleton, lead author of the first study, said from Anchorage. “This is a phenomenon which may increase and be seen in other populations,” said Singleton, a pediatrician and immunization consultant.

NOT Contagious, NO Epidemic, NO High Mortality

Currently, precancerous lesions are readily identifiable and treatable in the developed world. Cervical cancer causes approximately one percent of all cancer deaths in America. Studies thus far are inadequate. A unproven vaccine of questionable efftiveness is inappropriate.

Antibodies Do NOT Equal Immunity

When the “authorities” tell us that the vaccine is 70% effective, or some such number, it only means that the vaccine has been shown (in studies funded or influenced by drug companies) that the vaccine produced antibodies. But antibodies often have nothing to do with the chances an individual has of acquiring the virus, bacterium, or the disease itself. This vaccine was deemed “efective” in that it only produced humoral antibodies. There was no investigation as to extent or lack of cell-mediated (a more important kind of immune development) immunity related ot the vaccine.

Our Prediction

If history is any guide; there will be some number fudging. Downplaying the bad news and upstaging the promising is status quo with vaccination, but statistical slight-of-hand has been effectively staged before. Government officials and drug companies have much to lose, and “maintaining faith in vaccines”


Human papillomavirus (HPV) Vaccines by Brand

The pediatrician was persistent.

This was a life-saving vaccine, afterall. Why wouldn’t Theresa Tomoser want to vaccinate her 14-year-old daughter?

[WEB EXTRA: FDA’s Approval of Merck’s Gardisil]

In December 2009, the Tampa-area mother felt like she couldn’t put it off any longer and took her daughter, Danielle, to get the shot.

The shot was the first in a series of what should have been three doses of the quadrivalent human papillomavirus vaccine, better known as Gardisil.

Merck Pharmaceuticals was first approved by the Food and Drug Administration in 2006 to use Gardisil in females ages 9 to 26.

Merck’s research had shown the vaccine to prevent HPV types 16 and 18, which are the cause of about 70 percent of all cervical cancers, as well as types 6 and 11, which are responsible for genital warts.

Read Full Article:

By: By Lauren Sweeney, Special Projects Producer

Gardasil Quadrivalent human papillomavirus recombinant vaccine
Manufacturer Merck
Microorganism Human papillomavirus types 6, 11, 16, 18
Licensed 01/30/2007
Recommendations 3 intramuscular injections at 0, 2, 6 months — as young as 9 years old to 26 years old.
Ingredients Polysorbate 80, Sodium chloride, Sodium Borate, L-histidine hydrochloride, Aluminum hydroxyphosphate sulfate, Virus: Human papillomavirus (denatured) (HPV)
Product Descriptions

“Merck and the FDA have not been completely honest with the people about the pre-licensure clinical trials,” said NVIC president Barbara Loe Fisher. “Merck’s pre and post-licensure marketing strategy has positioned mass use of this vaccine by pre-teens as a morality play in order to avoid talking about the flawed science they used to get it licensed. This is not just about teenagers having sex, it is also about whether Gardasil has been proven safe and effective for little girls.”